At this tier some providers switch to higher-concentration vials, which changes injection volume but not much else
Medical Records: All records related to your GLP-1 drug prescription (dates, dosages), diagnosis of side effects (e.g., gastroparesis, pancreatitis, gallbladder issues), treatment plans, hospitalizations, surgeries, and follow-up care
Rybelsus activates GLP-1 receptors to help release more insulin when glucose is high, reduce the livers glucose output, slow stomach emptying and reduce appetite
Consider Semaglutide If: Established track record preferred Oral option needed (Rybelsus) Positive cardiovascular outcome data important (SELECT trial) Insurance covers better Prior GLP-1 experience More conservative approach preferred Consider Tirzepatide If: Maximum weight loss desired Better GI tolerability needed Greater glycemic control required Newer technology acceptable Dual mechanism benefits desired Cost difference minimal Decision Framework GLP-1 Research Peptides Semaglutide, Tirzepatide, and Retatrutide